StockNews.AI
BIOA
StockNews.AI
198 days

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioAge Labs

1. Faruqi & Faruqi investigates potential claims against BioAge Labs, Inc. 2. Claims include misleading statements about azelaprag's safety during clinical trials. 3. BioAge's stock fell from $20.09 to $4.65 following safety announcement. 4. Investors have until March 10, 2025, to seek lead plaintiff status. 5. Class action lawsuit highlights serious regulatory and financial risks for BioAge.

6m saved
Insight
Article

FAQ

Why Very Bearish?

The class action lawsuit can severely undermine investor confidence, similar to past biotech litigation cases.

How important is it?

The article directly addresses legal action against BioAge, likely affecting its market perception and value.

Why Short Term?

Legal proceedings could create immediate volatility in stock prices, affecting BIOA quickly, as seen in previous cases.

Related Companies

BIOA
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In BioAge To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in BioAge between September 26, 2024 and January 7, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information], /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioAge Labs, Inc. ("BioAge" or the "Company") (NASDAQ: BIOA) and reminds investors of the March 10, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi Logo (PRNewsfoto/Faruqi & Faruqi, LLP) Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) On December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 trial for azelaprag, its lead product candidate, citing safety concerns over elevated liver transaminase levels in participants. This came as a surprise because, at the time of its IPO less than three months earlier, BioAge highlighted azelaprag's potential in patients undergoing obesity therapy with incretin drugs. Following this news, BioAge's stock price declined from $20.09 per share on December 6, 2024 to $4.65 per share on December 7, 2024.The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding BioAge's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.To learn more about the BioAge Labs class action, go to www.faruqilaw.com/BIOA or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).Follow us for updates on LinkedIn, on X, or on Facebook.Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.SOURCE Faruqi & Faruqi, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News